Biovail Corporation

Biovail Receives Canadian Approval for Ralivia for the Treatment of Moderately Severe Pain

Published in Cardiovascular Business Week, September 9th, 2008

Biovail Corporation (NYSE:BVF)(TSX:BVF) announced that it has received an expanded indication for once-daily Ralivia(TM) - to include the treatment of moderately severe pain in addition to moderate pain - from the Therapeutic Products Directorate (TPD) in Canada. Ralivia(TM) is now indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more.

"This revised indication for moderately severe pain underscores the effectiveness of Ralivia(TM) in patients with moderate to moderately severe pain," said Biovail Chief Executive Officer Bill Wells. "Ralivia(TM) provides an analgesic option for patients with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Business Week

Source: Cardiovascular Business Week (2008-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry